{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"MTD is defined as highest dose level in which 6 patients treated with at most 1 experiencing a dose limiting toxicity (DLT) during 1st cycle. One cycle of therapy is 7 days of azacitidine (AZA) and 28 days of sorafenib. Starting dose of Sorafenib is 200 mg twice a day azacitidine","groups":[{"description":"Azacitidine (AZA) 75 mg/m\\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib starting dose 200 mg orally twice a day for 28 Day cycle.","id":"OG000","title":"Azacitidine + Sorafenib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 day cycle","title":"Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine","type":"PRIMARY","unitOfMeasure":"mg/twice daily"}